With the introduction of their IsoCap-AA radioisotope production technology, RadTran LLC has shifted its focus from consulting to technology development.  Over the past six years, RadTran Chief Executive Officer, Dr. Saleem Drera, has performed valuable technology consulting services for some of the biggest companies in the energy and space industries including NASA, URS, Thor Energy, and Aerojet Rocketdyne.  Dr. Drera’s vision for RadTran has always been to expand beyond consulting and into technology development.

“The rapid development and growth of Targeted Alpha Therapy cancer treatments and the need for high-purity radioisotopes to support their production presented the perfect opportunity to use our company’s expertise in nuclear technology to meet a need for society.  We believe our technology will provide a sustainable, environmentally conscious, and affordable supply of much needed radioisotopes.”  stated Dr. Drera, CEO of RadTran LLC

Progress toward development of the IsoCap-AA technology already includes the filing of a provisional patent application with the United States Patent and Trademark Office, the collaboration with government agencies on grant opportunities, and the identification of sites for possible proof of concept experimentation.  To support the expansion from consulting services to technology development, Dr. Drera has brought on three key employees: Dr. Andy Edwards, CTO, Nick Veith, COO, and Justin Smith, CFO.  Bios for the three new additions, along with that of Dr. Drera, can be found on the the RadTran website, RadTran.com.  RadTran is positioned well for the road ahead in commercializing their technology and anticipation is high.

“Pending their success in establishing proof-of-principle and scalability, we would be eager to engage them in their further development plans, and discuss options and avenues for mutual benefit.” Noted Dr. Eric Burak, Chief Scientific Officer at Fusion Pharmaceuticals.